3-methoxy-4-(5-methyl-1,3,4-oxadiazol-2-yl)aniline | 1239719-68-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-methoxy-4-(5-methyl-1,3,4-oxadiazol-2-yl)aniline
• 英文别名: 3-Methoxy-4-(5-methyl-1,3,4-oxadiazol-2-yl)aniline
• CAS: 1239719-68-6
• 化学式: C₁₀H₁₁N₃O₂
• 分子量: 205.216
• InChiKey: QWPJLPMUNJVMKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(2-Methoxy-4-nitrophenyl)-5-methyl-1,3,4-oxadiazole 在 tin(II) chloride dihdyrate 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以87%的产率得到3-methoxy-4-(5-methyl-1,3,4-oxadiazol-2-yl)aniline
  参考文献：
  名称：

  [EN] NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS
  [FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE

  摘要：

  本发明涉及式（I）的取代双环杂环化合物，其中Het1、Het2、A1、A2、A3和A4的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。

  公开号：

  WO2010089292A1

文献信息

• Fused pyrimidine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US10669276B2

  公开（公告）日：2020-06-02

  The present invention relates to compounds of formula I, wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, —CH2—C3-6-cycloalkyl, or bridged C3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halogen, lower alkyl or lower alkyl substituted by halogen; R2 is hydrogen, halogen, lower alkoxy, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R3 is a five membered heteroaryl group, selected from wherein R6 is hydrogen or lower alkyl; R7 is halogen or lower alkyl; R8 is hydrogen or lower alkyl; R9 is hydrogen or lower alkyl; R4 is lower alkyl or lower alkyl substituted by hydroxy; R5/R5′ is independently from each other hydrogen or lower alkyl; -( )n- is —CH2— or —CH2CH2— for n being 1 or 2; X is CH or N; or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

  本发明涉及式 I 的化合物、 其中 R1 是苯基、低级烷基、C3-6-环烷基、-CH2-C3-6-环烷基或桥接的 C3-5 环烷基，可任选被一个、两个或三个取代基取代，这些取代基选自卤素、低级烷基或被卤素取代的低级烷基； R2 是氢、卤素、低级烷氧基、被卤素取代的低级烷基或被卤素取代的低级烷氧基； R3 是五元杂芳基，选自 其中 R6 是氢或低级烷基 R7 是卤素或低级烷基 R8 是氢或低级烷基 R9 是氢或低级烷基； R4 是低级烷基或被羟基取代的低级烷基； R5/R5′互不独立地为氢或低级烷基； -()n-是-CH2-或-CH2CH2-，n为1或2； X 是 CH 或 N； 或其药用活性酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体和/或立体异构体。 这些化合物可用于治疗阿尔茨海默病、脑淀粉样变性血管病、遗传性脑出血伴淀粉样变性、荷兰型（HCHWA-D）、多梗塞性痴呆、帕金森痴呆或唐氏综合征。
• FUSED PYRIMIDINE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3481829B1

  公开（公告）日：2021-04-07
• NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS
  申请人：CELLZOME LIMITED

  公开号：US20150094311A1

  公开（公告）日：2015-04-02

  The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het 1 , Het 2 , A 1 , A 2 , A 3 and A 4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
• US8946426B2
  申请人：——

  公开号：US8946426B2

  公开（公告）日：2015-02-03
• [EN] NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010089292A1

  公开（公告）日：2010-08-12

  The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）的取代双环杂环化合物，其中Het1、Het2、A1、A2、A3和A4的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。